This week in Drug Discovery (5 – 9 January)
News round-up for 5 – 9 January by Bruno Quinney, Content Team at DDW.
This week in DDW, a new report finds breast cancer is the world’s most studied disease for the fifth year running. That same report predicts obesity to break into the top five, with weight loss a key theme across other headlines this week.
The top stories:
Breast cancer is world’s most studied disease, report finds
Phesi’s annual report into the world’s most studied diseases found that breast cancer was the most studied across all subtypes, from triple-negative to PIK3CA. Also in the top five were solid tumours, strokes, prostate cancer and non-small cell lung cancer (NSCLC).
RNAi-based therapeutics could treat obesity, results show
ARO-INHBE and ARO-ALK7 are investigational RNA interference (RNAi) therapeutics, developed by biotechnology company Arrowhead Pharmaceuticals. Preliminary results in Phase I/IIa trials found meaningful reductions in visceral fat, total fat and liver fat, suggesting both candidates could be effective treatments for obesity and metabolic diseases.
1.6 million UK patients used weight loss drugs in past year
The study, led by researchers at University College London, showed 1.6 million adults used drugs including Wegovy and Mounjaro to help lose weight between early 2024 and early 2025.
First-ever use of donor gum cells to treat osteoarthritis
Scarcell Therapeutics has treated the first patients with its allogenic gingival fibroblast (aGF) therapy using gum cells from a human donor as part of its Phase Ib clinical trial studying the therapy in knee osteoarthritis (OA).
Groundbreaking Huntington’s disease drug set for development
Biotechnology company LoQus23 Therapeutics has nominated its drug candidate LQT-23 for development as a treatment for Huntington’s Disease (HD).
